Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.gianpathlabs.com | |
Market Cap | 18.20 Cr. | |
Enterprise Value(EV) | 16.70 Cr. | 2021-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 1.95 | Trailing Twelve Months Ending 2021-03 |
Price-Earning Ratio (PE) | 9.02 | Trailing Twelve Months Ending 2021-03 |
Industry PE | 39.89 | Trailing Twelve Months Ending 2021-03 |
Book Value / Share | 17.62 | Trailing Twelve Months Ending 2021-03 |
Price to Book Value | 1.00 | Calculated using Price: 17.60 |
Dividend Yield | 0.00 | Period Ending 2021-03 |
No. of Shares Subscribed | 1.03 Cr. | 10,341,527 Shares |
FaceValue | 10 | |
Company Profile | ||
Gian Life Care was incorporated on November 06, 2018, under the provisions of the Companies Act, 2013 by Registrar of Companies, Kanpur. On March 01, 2019 the company took over the entire running business of Gian Pathology and X-Rays, a proprietorship concern of the promoter Arun Kumar Gupta with a view to provide diagnostic and related healthcare tests and services. Business area of the Company: The company is engaged in the business of providing diagnostic and related healthcare services. The company provides a wide range of diagnostic tests and services like patient diagnosis services, prevention, and wellness diagnosis services to patients and healthcare providers. The company caters to individual patients, hospitals, corporates and other healthcare providers. The company offers various tests including biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, histopathology, immunoassay, microbiology, molecular biology, and radiology services. Key Events and Milestones:
|
1 Day |
|
-4.86% |
1 Week |
|
-16.39% |
1 Month |
|
-38.46% |
3 Month |
|
-60.27% |
6 Month |
|
-62.77% |
1 Year |
|
+77.96% |
2 Year |
|
+193.33% |
5 Year |
|
|
10 Year |
|
3 years | 2019-03 | 2020-03 | 2021-03 | |
Return on Equity (%) | 90.94 | 29.34 | 23.33 | |
Return on Capital Employed (%) | 12.26 | 42.76 | 35.91 | |
Return on Assets (%) | 1.28 | 11.16 | 14.49 |
Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Shh. Funds | 0 | 8 | 10 | |
Non Curr. Liab. | 1 | 1 | 1 | |
Curr. Liab. | 7 | 4 | 5 | |
Minority Int. | ||||
Equity & Liab. | 8 | 12 | 15 | |
Non Curr. Assets | 4 | 8 | 9 | |
Curr. Assets | 3 | 4 | 6 | |
Misc. Exp. not W/O | ||||
Total Assets | 8 | 12 | 15 |
Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Net Sales | 1 | 8 | 10 | |
Other Income | 0 | 0 | ||
Total Income | 1 | 8 | 11 | |
Total Expenditure | 0 | -5 | -7 | |
PBIDT | 0 | 2 | 4 | |
Interest | 0 | -1 | -1 | |
Depreciation | 0 | 0 | 0 | |
Taxation | 0 | 0 | -1 | |
Exceptional Items | ||||
PAT | 0 | 1 | 2 | |
Adjusted EPS | 0 | 1 | 2 |
Particulars | 3 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
Cash Fr. Operatn. | 3 | 2 | 3 | |
Cash Fr. Inv. | -3 | -4 | -1 | |
Cash Fr. Finan. | 1 | 3 | 0 | |
Net Change | 1 | 0 | 1 | |
Cash & Cash Eqvt | 1 | 1 | 3 |
Tue, 24 May 2022
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Audited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year And Year Ended 31St March 2022 Gian Life Care Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2022 inter alia to consider and approve Pursuant to Regulation 29 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended from time to time we wish to intimate that the meeting of Board of Directors of the Company is scheduled to be held on Monday the 30th day of May 2022:-1. To interallia consider and approve Audited Standalone and Consolidated Financial results of the Company for the quarter/ half year and year ended 31st March 2022.2. Any other business which forms part of the Agenda Paper.Kindly take the same on record.Yours faithfully For GIAN LIFE CARE LIMITED |
Fri, 06 May 2022
Announcement under Regulation 30 (LODR)-Resignation of Chief Executive Officer (CEO) Dear Sir/Maam Subject: Intimation of Resignation of Chief Executive Officer under Regulation 30 (LODR)Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to intimate that the Company has received a letter from Mr. Sanjay Bhargava about his resignation from the post of Chief Executive Officer of the Company. |
Fri, 29 Apr 2022
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Dear Sir/Madam We enclose herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for period ended March 31 2022 for your information and record.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED |
Fri, 27 May 2022 |
|
|
|
|
|